Statistics from Altmetric.com
We recently administered a survey to investigate the prescribing of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care in the UK.
A Cochrane review did not find any evidence for how breakthrough pain should be managed in palliative care.1 Meta-analyses of randomised controlled trials have demonstrated increased efficacy of fentanyl compared with oral morphine,2 while pharmacokinetic studies highlight the onset and duration properties of fentanyl dosage forms that might be beneficial to certain patients experiencing breakthrough pain. Various dosage forms of fentanyl have been licenced for use in breakthrough cancer pain in adults, but UK National Institute for Health and Care Excellence (NICE) (2012) guidelines addressing strong opioid use in palliative care patients state that fentanyl should not be offered as first-line rescue medication. A lack of paediatric data for commercially available fentanyl transmucosal application systems means these products have traditionally not been recommended for first-line use in children.
The aim of this survey was to investigate current off-label prescribing of fentanyl for breakthrough pain relief in paediatric palliative care and to ascertain any barriers to use. This is timely as one of the research recommendations in the NICE guidelines (2016) on end of life care for infants, children and young people with life-limiting conditions related to managing breakthrough pain.3
An anonymous online survey was delivered via Qualtrics to …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.